MARKHAM, ON, Sept. 25, 2017 /CNW/ - MedReleaf Corp. (TSX:
LEAF) ("MedReleaf" or the "Company") announced the
results of the vote on the election of directors at the annual
meeting of shareholders held today.
On a vote by ballot, each of the five nominees proposed by
management was elected as a director of the Company to hold office
until the close of the next annual meeting of shareholders or until
the director's successor is elected or appointed.
|
Nominee
|
Votes
For
|
%
For
|
Votes
Withheld
|
%
Withheld
|
|
|
|
|
|
|
|
|
|
|
|
Norma
Beauchamp
|
55,205,572
|
99.92%
|
43,127
|
0.08%
|
|
|
|
|
|
|
Neil
Closner
|
55,204,807
|
99.92%
|
43,892
|
0.08%
|
|
|
|
|
|
|
Ronald
Funk
|
55,204,047
|
99.92%
|
44,652
|
0.08%
|
|
|
|
|
|
|
Deborah
Rosati
|
55,203,372
|
99.92%
|
45,327
|
0.08%
|
|
|
|
|
|
|
Lloyd M.
Segal
|
55,205,147
|
99.92%
|
43,552
|
0.08%
|
About MedReleaf Corp.
MedReleaf sets The Medical Grade Standard™ for cannabis in
Canada and around the world. The
first and only ICHGMP and ISO 9001 certified cannabis producer in
North America, MedReleaf is a
R&D-driven company dedicated to patient care, scientific
innovation, research and advancing the understanding of the
therapeutic benefits of cannabis. Sourced from around the world and
perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of
premium products to patients seeking safe, consistent and effective
medical cannabis.
For more information on MedReleaf, its products, research and
how the Company is helping patients #livefree, please visit
MedReleaf.com or follow @medreleaf.
SOURCE MedReleaf Corp.